Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.39 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1553332 | 0.85 | GPR88 (0.40) | CTSSCTSKNQO2MAP1LC3BMAP1LC3A | |
| SCHEMBL29747547 | 0.82 | JAK2 (0.43) | CTSSCTSKMAPK1PPARAATM | |
| SCHEMBL10270101 | 0.82 | JAK2 (0.43) | CTSSCTSKMAPK1PPARAATM | |
| SCHEMBL29748599 | 0.82 | JAK2 (0.43) | CTSSCTSKMAPK1PPARAATM | |
| SCHEMBL1555587 | 0.81 | GPR88 (0.50) | CTSSGPR88PPARAATMACE | |
| SCHEMBL2898215 | 0.80 | CTSS (0.41) | CTSSCTSKNQO2MAP1LC3BMAP1LC3A | |
| SCHEMBL2897029 | 0.80 | CTSS (0.39) | CTSSCTSKNQO2MAP1LC3BMAP1LC3A | |
| SCHEMBL2011973 | 0.79 | CTSS (0.47) | CTSSCTSKGPR88MIFPPARA | |
| SCHEMBL25533312 | 0.79 | CTSS (0.47) | CTSSCTSKGPR88MIFPPARA | |
| SCHEMBL1553363 | 0.79 | CTSS (0.47) | CTSSCTSKGPR88MIFPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497271-B2 | Modulators of G protein-coupled receptor 88 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-30 | — | — | US | disclosed |
| EP-2486030-B1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | BRISTOL MYERS SQUIBB CO (US) | 2013-07-24 | — | — | EP | disclosed |
| EP-2486030-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | Bristol-Myers Squibb Company (US) | 2012-08-15 | — | — | EP | disclosed |
| US-20110245264-A1 | Modulators of G Protein-Coupled Receptor 88 | Bristol-Myers Squibb Company and Lexicon Pharmaceuticals, Inc. | 2011-10-06 | — | — | US | disclosed |
| WO-2011044195-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245264-A1 | Modulators of G Protein-Coupled Receptor 88 | GPR88, GPR68, GRK2 | CTSS 4468/4885CTSK 4010/4885NQO2 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.